Abstract
BackgroundIn a Phase 2 study, Guselkumab (GUS) was shown to be safe and effective in patients (pts) w/active psoriatic arthritis (PsA) w/meaningful improvements in enthesitis.ObjectivesTo evaluate the effect of GUS...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have